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Summary 
Whereas dendritic cells (DC) are known to be potent activators of T  cells both in vitro and 
in vivo, the critical costimulatory molecules expressed on DC are not well characterized. Using 
immunocytochemical and molecular techniques we find that splenic DC express B7/BB1,  the 
counter-receptor for CD28. Moreover, expression of B7/BB1 is upregulated on epidermal Langerhans 
cells (I.C) during their functional maturation into potent T cell stimulators. In blocking experiments, 
we find that participation of B7/BB1 is required for optimal proliferation of unprimed, allogeneic 
T cells in DC-driven, primary mixed leukocyte reactions. These data demonstrate that the regulated 
expression of B7/BB1 on DC may be important in the initiation of a primary T cell response. 
D 
endritic cells (DC), and to a lesser extent B cell blasts, 
are the principal activators of resting T  cells in both 
murine and human in vitro T cell proliferation assays (1, 2). 
Moreover, DC are the most potent initiators of primary T 
cell responses in vivo (3). The identity of the critical costimula- 
tory signals for resting T cell activation possessed by DC and 
B blasts  has remained elusive.  Failure of DC to synthesize 
ILl  dispelled the notion  that  this  cytokine is  the critical 
"second signal" (4).  Likewise, although intercellular adhe- 
sion molecule 1 (ICAM-1)/LFA-1 and LFA-3/CD2 are im- 
portant adhesion and costimulatory molecules, their distri- 
bution on a variety of cell types indicates that their expression 
alone would not account for the unique ability of DC and 
B blasts to  activate resting T  cells  (5). 
Recent attention has focused on CD28, which is expressed 
on most CO4 + and '~50%  of CO8 + T  cells, as a putative 
receptor of the second signal required for T  cell activation 
(for review see reference 6). A homologous molecule, CTLA4, 
has been cloned from cytotoxic T  cells,  suggesting that a 
member of the CD28 family of accessory molecules may be 
expressed on all T cells (7).  Signals delivered via CD28 en- 
hance cytokine gene transcription (8), stabilize cytokine mes- 
sage (9), and are required for optimal proliferation and cytokine 
release by CO4 + T  cells  and Thl cell lines (10,  11). 
A ligand for CD28, B7/BB1 (12), has been identified on 
IFN-3,-treated monocytes (13) and activated, but not resting 
B cells (14).  There is evidence indicating that its participa- 
tion may be important in the activation of resting T  cells 
in the MLK (15).  In light of their stimulatory properties, 
it seems likely that DC express B7/BB1 or a similar CD28 
counter-receptor. Moreover, knowledge that DC exist in dis- 
tinct phenotypic and functional forms suggests that the ex- 
pression of B7/BB1 may be regulated in DC. Resident Langer- 
hans cells (LC), the DC of skin, can process antigens, but 
are poor activators of resting T  cells (16,  17). However, in 
bulk epidermal cell cultures,  under  the regulation of the 
cytokine GM-CSF, LC mature into extremely potent T cells 
stimulators (18). Although the molecular mechanisms respon- 
sible for Langerhans cell maturation are unknown, the char- 
acteristics of B7/BB1 suggest that it may play an important 
role in this process. 
Materials and Methods 
Mice.  Male  C57BL/10,  BALB/c, C3H/He,  B10.BK, and 
DBA/2 mice (7-12-wk-old) were obtained from Harlan Sprague 
Dawley, Inc. (Indianapolis, IN) or The Jackson Laboratory (Bar 
Harbor, ME). 
Antibodies.  The following were used as primary antibodies for 
flow cytometric analysis: TIB 145, rat anti-mouse P50 (B cell re- 
stricted; American Type Culture Collection, KockviUe,  ME)); N418 
(19), hamster  anti-mouse CDllc (DC restricted in mice); bio- 
tinylated B21-2, rat anti-mouse Ia  b'd (kind gift from Justin  A. 
Koake and Jonathan M.  Austyn,  University  of Oxford);  and 
anti-CD4-PE (Becton Dickinson & Co., Mountain View, CA). 
The CTLA4-Ig fusion protein, contains the extracellular por- 
tion of human CTLA4 and an Ig C3' chain, and the B7-Ig fusion 
protein is comprised of the extraceUular  portion of human B7 and 
the same Ig C't chain (7). CTLA4-Ig binds to human, rat, and 
mouse B7/BB1 in the concentration range used in these studies 
(3-30 #g/ml). B7-Ig has very low avidity for human and murine 
CD28,  and shows very little binding in the same concentration 
range ([7] and Peter Linsley, unpublished observations). 
Second-stage reagents and antibodies used for these experiments 
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ical Co., St. Louis, MO),  biotin and FITC conjugates of rabbit 
anti-hamster IgG (Accurate Chemical & Scientific Corp., West- 
bury, NY), biotin and FITC conjugates  of  goat anti-rat-IgG (Sigma 
Chemical Co.), and streptavidin-PE (Becton Dickinson & Co.). 
Splenic Dendritic Cells.  DC-enriched populations were prepared 
as low-buoyant  density, transiently-adherent  cells from mouse spleen 
cell suspensions (20). DC within these preparations were labeled 
with the hamster anti-mouse DC mAb, N418, followed by bio- 
tinylated rabbit anti-hamster IgG (Accurate Chemical & Scientific 
Corp.), and finally streptavidin-PE (Becton Dickinson & Co.). 
Epidermal CeUSuspensions.  Epidermal  sheets were prepared using 
2.5x  trypsin/EDTA (Sigma Chemical Co.) essentially  as described 
(18). The cells released from the sheets were passed through 100 
#m nylon filters, pelleted, and counted. The resultant epidermal 
cell suspension (2-5% Langerhans cells) were either used immedi- 
ately (fresh EC, ECf) or cultured (cultured EC, ECc) at a density 
of 1-2  x  106/ml in complete media (R.PMI 1640 containing 5% 
FCS, 2 mM glutamine, and antibiotics, 2.5  x  10 -S M 2-ME) for 
3d. 
T Cells.  Primary T cell-enriched populations were prepared 
from  unfractionated  spleen cell suspensions as  nylon  wool- 
nonadherent cells followed  by red cell lysis in Tris-buffered ammo- 
nium chloride. EDS-1 is an alloreactive  (B10.BR anti-C57BL/10) 
CD4 + T cell line derived in our laboratory. 
LPS-activated Stdenocytes.  Spleen  cell suspensions were depleted 
of red cells using Tris-buffered ammonium chloride. Splenocytes 
were cultured at 106/ml in complete media containing 10 #g/ml 
LPS (Escherichia coli B5;055, Sigma Chemical Co.) for 72 h. 
Flow  Cytometric Analysis.  Cell populations  were labeled as 
follows: splenic  DC were labeled  with the hamster anti-mouse DC 
mAb, N418, followed  by biotinylated  rat anti-hamster-IgG blocked 
with 5% normal mouse serum and then streptavidin-PE.  LC within 
epidermal cell suspensions were labeled with biotinylated B21-2 
(anti-Ia  b.a) followed by streptavidin-PE, the only Ia § cells within 
epidermal cell suspensions being LC (16). B cells were identified 
with the rat mAb, TIB 145, a B cell-restricted marker, followed 
by FITC conjugate goat anti-rat IgG blocked with 5% normal 
mouse serum. Negative controls were either rat anti-horseradish 
peroxidase or no primary. 
B7/BB1 expression on the various cell populations was assessed 
using the CTLA4-Ig fusion  protein at 3-5 #g/ml followed  by FITC- 
conjugated goat anti-human IgG, blocked with 5% normal mouse 
serum.  Negative controls included the B7-Ig fusion protein (5 
#g/ml), human IgG (10 #g/ml) (Sigma Chemical Co.), or no pri- 
mary reagent with equivalent results. 
Fluorescence profiles were generated using a FACScan  |  flow 
cytometer and Consort 30 software (Becton Dickinson & Co.). 
Sterile cell sorts were performed on a FACStar  |  flow cytometer 
(Becton Dickinson & Co.). 
T Cell Proliferation Assays.  In allogeneic MLR, graded doses 
of irradiated (2,000 tad, 137Cs) stimulator cells were added to 4  x 
10  s allogeneic nylon wool-passed responder cells in a final volume 
of 150 #1 in 96-well round-bottomed  microtest plates. Prolifera- 
tion was measured by adding  1 /zCi of [3H]methyl-thymidine 
(Amersham Corp., Arlington Heights, IL)/well after 72 h. The 
cells were harvested 12-16 h later and counted on a BetaPlate 
Counter (LKB  Instruments, Inc., Gaithersburg, MD). Results are 
the means of triplicate cultures. 
PCR.  mRNA was prepared from 3-8  x  106 LPS-activated 
splenocytes, or 2  x  10  s sorted DC using  the  Microfast Tract 
System (Invitrogen, San Diego, CA), which employs  SDS lysis  fol- 
lowed by isolation of mRNA on oligo dT cellulose. First-strand 
cDNA synthesis was performed using avian myeloblastosis  reverse 
transcriptase (Invitrogen) using an oligo dT primer. PCR was car- 
ried out in a 50-#1 volume using 5 #1 of cDNA, 5 #1 10x  PCR 
reaction buffer (Amersham Corp.), 1.5 U Hot tub DNA polymerase 
(Amersham Corp.), 0.5 mM dNTPs, 50 pmol of forward and re- 
verse oligonucleotide primers (5'ATGGCTTGCAATTGTCAGY- 
sense, nucleotides  249-266 of the murine B7/BB1 cDNA sequence 
and 5'CTAAAGGAAGACGGTCTY-antisense,  nucleotides 1153- 
1169), synthesized at the Microchemical Facility of the Winship 
Cancer Center, Emory University (21). The coding sequence of 
murine B7/BB1 gene is composed of at least five exons and spans 
'~20 kb (21). Since the oligonucleotide primers used in these ex- 
periments come from different exons (i.e., include the start and 
stop codons, respectively),  amplification  of  contaminating genomic 
DNA would yield distinctly different sized product (i.e., •20  kb) 
than the ,,o920 bp product seen in our reactions. Reactions were 
carried out for 40 cycles of 95~  for 1 min, 50~  for 45 s, and 
72~  for 1 min in a thermocycler  (Perkin-Elmer Cetus Corp., Nor- 
walk, CT). 
The PCR products were analyzed by agarose gel electropho- 
resis, transferred to nylon membranes (Tropix, Inc., Orem, UT), 
then immobilized by UV fixation. The blots were probed with 
a biotinyhted internal B7/BB1 oligonucleotide  (5' AGTTGTCCAT- 
CAAAGCTGAC 3', nucleotides 661-680, synthesized and labeled 
by the Microchemical  Facility  of the Winship Cancer Center). The 
biotinylated probe and marker tract  were visualized using the 
Southern Light chemiluminescence system (Tropix, Inc.). 
Results and Discussion 
Splenic Dendritic  Cells Express the Costiraulatory  Molecule, 
BT/BB1.  Our initial experiments were designed to study 
the expression of the B7/BB1 costimulatory  molecule on mu- 
rine cell populations with particular emphasis on determining 
whether B7 is expressed on mature immunostimulatory  den- 
dritic cells.  As there are  no mAbs that recognize murine 
BT/BB1, we used the CTLA4-Ig fusion protein as the first 
stage reagent for FACS  |  analysis. As noted in the introduc- 
tion, CTLA4 is a natural ligand for B7/BB1. Using the PCR, 
Linsley et al. (7) have developed  a fusion protein that con- 
tains the binding region of CTLA4 and the C region of the 
human IgG H chain. Their studies with this fusion protein 
have demonstrated its use as a probe that binds to human, 
rat, and mouse B7/BB1 ([7], and Peter Linsley, unpublished 
observations). 
DC-enriched low density, transiently-adherent spleen ceUs 
were  analyzed for expression of B7  using  two-color im- 
munofluorescence on the flow cytometer. For comparison, 
LPS-activated  B cell blasts and a CD4 + T  cell line, EDS-1 
were also evaluated. As expected, the T call line failed to ex- 
press  a CTLA4 counter-receptor (Fig.  1 c),  whereas LPS- 
activated B cells strongly expressed  a ligand for CTLA4-Ig 
(Fig.  1 d).  In addition, we found that N418  positive im- 
munostimulatory DC also  strongly bound the CTLA4-Ig 
fusion protein, but not the BT-Ig fusion protein (Fig.  1, a 
and b) or human IgG (data not shown). In contrast, the N418- 
negative fraction, which is composed of T cells, B cells, and 
macrophages, failed to label with CTLA4-Ig. These binding 
studies provided initial evidence that DC and LPS-activated 
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Figure 1.  Immunostimulatory dendritic cells and LPS-activated B cells 
express B7/BB1. Dendritic cell-enriched populations were prepared from 
C57BL/10 spleens and labeled with N418 (a hamster anti-mouse DC mAb). 
B7 expression was assessed on the DC (PE positive) using the CTLA4-Ig 
fusion protein as a first-stage reagent followed by FITC-conjugated goat 
anti-human IgG. For comparison, LPS-activated B cell blasts and a CD4- 
positive alloreactive T cell line (EDS-1) were also studied. (a) Splenic den- 
dritic cells labeled with both N418 and CTLA4-Ig. (b) Splenic DC failed 
to label with the control B7-Ig fusion protein. In contrast, the CD4-positive 
a11oreactive T cell line failed to bind CTLA4-Ig (c). LPS-activated B cell 
blasts which uniformly expressed TIB 145 (a B cell-restricted  marker; not 
shown) also expressed BT/BB1  (d) when analyzed by single-color flow 
cytometry. (.  ￿9  .)  Negative control, (  ) CTLA4-Ig. Two-color data 
(a-c) depict log fluorescence intensity on both x and y axes. Single-color 
histogram (d) depicts log fluorescence intensity on the x axis, and relative 
cell number on the y  axis.  (Similar results have been obtained in three 
experiments). 
B cell blasts,  but  not T  cells, express B7/BB1  or a novel 
counter-receptor/ligand for CTLA4. 
In an attempt to distinguish between these possibilities, 
we used  the  PCK  to  detect B7/BB1  transcripts.  Highly 
purified DC populations were isolated by fluorescence acti- 
vated cell sorting N418 positive cells from low-buoyant den- 
sity, transiently-adherent spleen cell suspensions, mKNA from 
these cells and from LPS-activated splenocytes was prepared, 
followed by first-strand  cDNA synthesized on an oligo dT 
primer, cDNA from the populations was then amplified using 
specific  B7/BB1 oligonucleotide primers (21). PCK products 
were analyzed by agarose gel electrophoresis. Using this ap- 
proach we detected similar sized PCK products ('~920  and 
'~800 bp) from both LPS-activated blasts and dendritic cell 
preparations, but not from reactions in which no cDNA tem- 
plate was added (Fig. 2 a).  Specificity of the amplification 
was confirmed by hybridizing Southern blots of the gels with 
a biotinylated B7/BB1  oligonucleotide probe which is con- 
tained within the DNA amplified by the PCK primers. Both 
the '~920 and the "o800 bp bands hybridized with the B7 
Figure 2.  Dendritic cells and LPS-activated  B  cells express B7/BB1 
mRNA. mRNA was prepared from 2  x  10  s sorted N418-positive  DC 
or 5  x  10~ LPS blasts foUowed by cDNA synthesis (20 #1 final volume). 
5 #1 ofcDNA was then amplified using specific BT/BB1 oligo nudeotide 
primers from different  exons of the coding sequence.  PCR was carried 
out for 40 cycles and analyzed on ethidium bromide-stained 1.5% agarose 
gds. (a) Similar '~920 and '~800 bp bands were seen in PCK reactions 
of cDNA from LPS blasts (lane 3) and dendritic cells (lane 4), but not 
in PCR samples with no cDNA added (lane 2). (b) Southern blots of the 
gels were then probed with an internal biotinylated B7 oligonucleotide 
probe confirming the specificity of the amplification. Lanes I, DNA mo- 
lecular weight standards (1 kb ladder, Gibco BILL, Gaithersburg, MD); 
2, no cDNA; 3, LPS blasts; 4, dendritic cells; and 5, biotinylated DNA 
M.W. standards  (X DNA EcoRI, HindlII; Sigma Chemical Co.). 
oligo probe (Fig.  2 b) but not with a ~/-actin probe (data 
not shown). B7 KNA transcripts  of 10, 4.2,  2.9,  and 1.7 
kb and protein products with molecular masses ranging from 
45 to 66 kD have been reported (14, 21). 
Together, the two-color flow cytometric data showing cell 
surface expression of a CTLA4 ligand, and the PCR data 
demonstrating presence of B7/BB1  mKNA in splenic DC 
provide convincing evidence that splenic DC express B7/BB1. 
However, we cannot formally exclude the possibility that DC 
may also express an additional  novel CTLA4 ligand. 
BT/BB1 Expression Is Upregulated on Epidermal Langerhans 
Cells during Their Functional Maturation In  Vitro.  As noted 
earlier, freshly isolated LC (LCf) display numerous pheno- 
typic differences from DC isolated from lymphoid tissues. 
However, in culture, LC (LCc) "mature" into cells that are 
virtually phenotypically and functionally indistinguishable 
from lymphoid DC (16, 18). LCf are relatively weak stimu- 
lators of resting T cells, whereas LCc are extremely potent 
T cell activators (16). Similarly, we find that freshly prepared 
bulk epidermal cell suspensions (ECf) are weak stimulators 
of allogeneic T  cells, whereas cultured bulk EC (ECc) in- 
duce vigorous proliferation  of allogeneic T cells (Fig. 3 a). 
Previous studies have demonstrated that these differences in 
stimulatory capacity of ECf and ECc are a reflection of LC 
maturation, and that these phenotypic and functional changes 
are induced by the cytokine GM-CSF  (18). 
We sought to test the hypothesis that differential expres- 
sion of the BT/BB1 costimulatory molecule by mature LC 
may  be  responsible  for  the  observed  differences  in  im- 
munostimulatory function of freshly isolated and cultured 
Langerhans cells. Consistent with this notion, we have found 
that expression of B7 is strongly upregulated on epidermal 
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Figure 3.  Epidermal LC upregulate expression of 
B7 during their functional maturation in culture. (a) 
Graded doses of irradiated freshly isolated (open circles) 
or cultured (closed  diamonds)  C57BL/10 epidermal  cells 
were added to 4  x  10s nylon wool passed B10.BR 
T calls in round-bottomed 96-well microtest plates. 
T cell proliferation was measured as [3H]thymidine 
incorporation after 72 h in culture. Results are means 
of triplicate cultures. As reported by Freeman et al. 
(21), we found that cultured EC are many times more 
potent T cell stimulators than freshly isolated EC. B7 
expression was assessed  on fleshly isolated and cultured 
I.C (3 d) using two-color flow cytometry. (b) Freshly 
isolated LC do  not  express detectable levels of B7 
(CTLA4 binding) relative to the negative control. In 
contrast, (c) cultured I.C strongly express B7. (. - -) 
Negative control; (  ) CTLA4-Ig. Negative con- 
trois have included B7-Ig, human IgG, and no pri- 
mary with identical results. Single-color histograms 
(b and c) depict log fluorescence intensity on the x 
axis and relative cell number on the y axis. Similar 
results have  been obtained in three experiments. Failure 
to labd fleshly isolated LC is not an artifact of the 
isolation procedure as the level of CTLA4-Ig binding 
on the Ia  + LC was only minimally altered after reex- 
posure of bulk EC to 2.5x  trypsin/EDTA for 10 rain 
at  37~  CTLA4-Ig  mean  channd  fluorescence- 
negative control on I.Cc is 975, and after reexposure 
to trypsin, 882. Similar  results were obtained for splenic 
DC and LPS-activated B cell blasts. 
LC during their maturation into potent T  cell stimulators. 
LC within epidermal cell suspensions were labeled with bio- 
tinylated B21-2 followed by streptavidin-PE. B7/BB1 expres- 
sion was again assessed using CTLA-Ig followed by FITC- 
conjugated goat anti-human IgG. The cell populations were 
then analyzed using two-color flow cytometry.  Using  this 
approach,  LCf did  not  express  detectable  levels  of B7.  In 
marked contrast,  LCc were found  to express high levels of 
B7  (Fig.  3,  b and c).  These results  could  not  be explained 
by recovery of a trypsin-sensitive marker since reexposure of 
cultured EC to trypsin/EDTA did not significantly affect ex- 
pression of B7/BB1  on the LCc (see Fig. 3 legend). The Ia- 
negative fraction,  which  is composed of keratinocytes  and 
3'/$ T  cells failed to label with CTLA4-Ig in fresh and cul- 
tured  preparations  (data  not  shown). 
Participation of B7/BB1 Is Required for Activation of Resting 
Allogeneic T Cells by Splenic Dendritic Cells, and Antigen-driven 
Proliferation of Thl Cells,  To explore the functional role of 
B7/BB1 on DC during the initiation of T  cell responses, we 
tested the ability of CTLA4-Ig to inhibit dendritic cell-driven 
primary allogeneic MLR. We find that CTLA4-Ig produces 
a dose-dependent  inhibition  of the allo MLR, whereas nei- 
ther human  IgG nor the BT-Ig altered DC-induced  T  call 
proliferation (Fig. 4). Although this data demonstrates that 
B7 is a critical accessory molecule in DC-driven primary T 
cell responses, it remains unclear whether CTLA4-Ig inhibits 
the MLR exclusively by blocking signal transduction through 
CD28, or if blocking B7/BB1-CD28-mediated adhesion also 
contributes to the inhibition of DC-induced T  ceU prolifera- 
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Figure 4.  CTLA4-Ig inhibits dendritic cell-induced T cell proliferation 
in an alloganeic MLR.  Unprimed C3H/He nylon wool-passed T cells 
(4  x  10S/weU)  were stimulated with 10  s C57BL/10 dendritic cells in the 
presence of increasing doses of CTLA4-1g, B7-Ig, or human IgG. T cell 
proliferation was measured as [3H]thymidine incorporation after 3 d and 
is expressed  as the percentage  of incorporation in untreated cultures. Results 
shown are the means of triplicate cultures. Addition of CTLA4-Ig (closed 
c/rcks) resulted in a dose-dependent  inhibition of proliferation  whereas  neither 
B7-1g (closed  triangles),  which has very low avidity for mouse CD28, nor 
human IgG (open  squares) affected  the proliferative  response. Similar results 
have been obtained in three experiments. 
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Ig, but confirmation of these observations will require the 
development  of semiquantitative  cluster assays. 
As noted above, signals delivered via CD28 augment re- 
lease of I1.-2 and IFN-%  but not Ib4,  suggesting that  the 
effect of CD28  signaling  may differ in Thl  and Th2.  We 
have also observed that  CTLA4-Ig inhibits antigen-specific 
proliferative  responses of a Thl done, but has much less effect 
on the specific proliferation of a Th2 clone (our unpublished 
observations). Analysis of additional Thl and Th2 clones will 
be required to assess the significance of these preliminary ob- 
servations. 
In summary, we find that: (a) mature splenic dendritic cells 
express B7/BB1 (during the preparation of this manuscript 
we have become aware that another group has described similar 
expression [22]); (b) epidermal Langerhans  cells upregulate 
expression of B7 during their functional maturation into po- 
tent T  cell stimulators;  and (c) B7/BB1 expression by den- 
dritic cells is of critical importance in the activation of un- 
primed  allogeneic T  cells. 
The distribution,  functional, and migratory properties of 
dendritic cells are ideally suited to their role as specialized 
initiators  of T  cell-mediated immune  responses.  Our  data 
bring  together  the  observations  that  DC  upregulate  im- 
munostimulatory function during their migration from pe- 
ripheral tissues into T  cell regions of lymphoid tissues (23, 
24) and provide evidence that  expression of B7/BB1 plays 
a critical role in this process. Further studies on the cytokines 
that regulate the expression and function of B7/BB1 on den- 
dritic cells and other APC may provide additional insights 
into the mechanisms involved in the initiation and amplifica- 
tion of T  cell-mediated immune responses, and lead to the 
development of new strategies to up- or downregulate this 
molecule and thus augment (e.g., vaccination),  interrupt (e.g., 
allograft rejection),  or alter the character  (Th2  vs. Thl)  of 
nascent or ongoing immune  responses. 
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